ERBB2 and neoplasm: Further subgroup analyses by tumor subtype and treatment regimen revealed mOS was 12.24 months (95%CI: 8.58-17.48) for mTNBC patients and 12.00 months (95%CI: 8.44-17.06) for HR+/HER2- mBC patients (Figure 4E).